This white paper presents a clinical study evaluating MV-Flow™ and its Vascularity Index (VI) for differentiating benign and malignant adnexal masses using ultrasound imaging. Conducted at the First Affiliated Hospital of Xinjiang Medical University, the study assessed 107 patients with 115 adnexal tumors using the Samsung HERA W10 system.
MV-Flow™ is a microvascular ultrasound technology designed to detect low-velocity blood flow that conventional Doppler may miss. Its Vascularity Index quantitatively measures the ratio of blood flow within a defined region of interest, helping clinicians evaluate vascularity levels associated with tumor characteristics.
Findings revealed that malignant adnexal tumors, including various forms of ovarian cancer, demonstrated significantly higher VI values and centrally concentrated, linear vascular patterns. In contrast, benign tumors showed sparse or peripheral vascularity. Using a VI cutoff of 7.15%, the diagnostic performance reached an AUC of 0.918, with 84.85% sensitivity and 91.46% specificity.
The study also reported excellent inter-observer consistency (ICC = 0.987), indicating that the Vascularity Index is reproducible in clinical settings. Compared with the O-RADS ultrasound system, MV-Flow™ and its Vascularity Index provided similarly high diagnostic accuracy with a more simplified measurement process.
The conclusion affirms that MV-Flow™ and its Vascularity Index are effective for the ultrasound-based evaluation of adnexal masses, providing a microvascular imaging solution that supports early and reliable identification of potential malignancy, including ovarian cancer.
For a practical overview of MV-Flow™ imaging using the HERA W10 Elite system, refer to this Quick Guide to MV-Flow™ .
